drugset / Trial / NCT04543916
Venetoclax and Irinotecan in Relapsed/Refractory SCLC
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is a single-arm, open-label, multicenter phase 1/2 trial designed to establish the recommended phase 2 dose (RP2D) of daily oral venetoclax when given in combination with irinotecan in patients with relapsed or refractory small cell lung cancer (SCLC).
Timeline
- Start
- 2021-06-30
- Primary completion
- 2028-05-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 50 mg | Oral |
| Subject | Venetoclax | Small molecule | 100 mg | Oral |
| Subject | Venetoclax | Small molecule | 200 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |
| Subject | Venetoclax | Small molecule | 600 mg | Oral |